Scottish device developer 1nhaler has announced the closing of a £1.5 million funding led by Archangels, with proceeds intended for continued development the company’s disposable single-use dry powder inhaler. The company says that funds will go toward clinical trial material manufacturing by Upperton and scale-up of the manufacturing process by Harro Höfliger, with the goal of a regulatory submission to UK authorities by the end of 2027.
The 1nhaler DPI is stored as a flat piece of cardboard about the size of a credit card that can be popped open at the time of use. According to the company, “Performance data from 1nhaler’s lead product demonstrates results on par with leading multidose dry powder inhalers.” In 2023, 1nhaler announced that it had raised £2 million for development of the cardboard DPI and in 2024, the company announced several board appointments.
1nhaler CEO Lisa McMyn, co-founder and Chief Executive Officer at 1nhaler, said: “This additional funding represents strong continued confidence in our technology platform and our progress towards commercialization. The support from Archangels, Scottish Enterprise and BBB Investments is enabling us to advance our clinical and manufacturing capabilities as we work towards regulatory approval. Our platform has the potential to become the simplest, most convenient single-dose, disposable inhaler on the market, transforming the delivery of inhalable drugs without the cost and environmental impact of existing devices.”
Read the 1nhaler press release
